Skip to content

Evaluation of the efficacy and safety of remifentanil combined with remimazolam in elderly patients undergoing painless gastroscopy examination

Evaluation of the efficacy and safety of remifentanil combined with remimazolam in elderly patients undergoing painless gastroscopy examination

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102113
Enrollment
Unknown
Registered
2025-05-08
Start date
2022-11-07
Completion date
Unknown
Last updated
2025-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

painless gastroscopy

Interventions

Non-gender group:Upon entering the examination room, the patients underwent standard monitoring before receiving a gradual intravenous infusion of remifentanil at a rate of 0.5µg/kg,followed by an in
if not,it was decreased by the same amount.The point at which positive reactions transitioned to negative ones was identified as the crossover point, with the study concluding after seven crossover po
Male group:Upon entering the examination room, the patients underwent standard monitoring before receiving a gradual intravenous infusion of remifentanil at a rate of 0.5µg/kg,followed by an initial i
Female group:Upon entering the examination room, the patients underwent standard monitoring before receiving a gradual intravenous infusion of remifentanil at a rate of 0.5µg/kg,followed by an initial

Sponsors

The First Affiliated Hospital of Xi'an Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients set to undergo painless gastroscopy; 2. Age 65 years or older; 3. American Society of Anesthesiologists (ASA) classification levels I-III; 4. remimazolam and femifentanil were useded.

Exclusion criteria

Exclusion criteria: 1. Previous allergic reactions to benzodiazepines or their ingredients; 2. Chronic alcohol or drug addiction; 3. Schizophrenia and major depressive disorder; 4. Severe obesity and obstructive sleep apnea; 5. Recent upper respiratory infections or worsening asthma; 6. Uncontrolled high blood pressure or unstable angina; 7. Significant liver impairment, acute upper GI bleeding with shock, severe anemia, or gastrointestinal blockage with retained gastric contents; 8. Angle-closure glaucoma; 9. History of prolonged use of sedatives and pain relievers; 10. Myasthenia gravis.

Design outcomes

Primary

MeasureTime frame
half-effective dose;95% effective dose;

Secondary

MeasureTime frame
Heart rate;arterial pressure;espiratory rate;oxygen saturation;adverse reaction;

Countries

China

Contacts

Public ContactDanni Lyu

The First Affiliated Hospital of Xi'an Medical University

lvdanni19890216@163.com+86 134 8495 4598

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026